Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
3.670
-0.160 (-4.18%)
Jul 29, 2026, 1:25 PM EDT - Market open
Larimar Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Larimar Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $14.4. The average 1-year stock price forecast is 292.37% higher than the current stock price, while the lowest is $5.00 (+36.24%) and the highest is $26 (+608.45%).
Price Target: $14.4 (+292.37%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Larimar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 8 | 8 | 9 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $25 | Buy | Maintains | $25 | +581.20% | Jul 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Initiates $10 | Buy | Initiates | $10 | +172.48% | Jul 2, 2026 |
| Wedbush | Wedbush | Buy Maintains $12 | Buy | Maintains | $12 | +226.98% | Jun 30, 2026 |
| Robert W. Baird | Robert W. Baird | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +36.24% | Jun 30, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $9 | Buy | Reiterates | $9 | +145.23% | Jun 30, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
57.06M
EPS This Year
-1.61
from -2.27
EPS Next Year
-1.18
from -1.61
EPS and Forward PE are based on non-GAAP adjusted numbers.